Houston Concierge Medicine Partners With Cardio Diagnostics to Offer the Epi+Gen CHD Test in Their Executive Health Program
HOUSTON–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Houston Concierge Medicine, a leading medical practice serving Houston’s health executives and consumers, today announced the use of Cardio’s Epi+Gen Diagnostics Test CHD. This test, which combines epigenetics, genetics, high-performance computing and AI to identify those at risk for coronary heart disease, is now available to Houston Concierge Medicine patients as part of their Executive Program of Health.
Executive physicals are becoming more common as employers recognize the long-term value of preventive care and wellness for their executives. Executive physicals are important employee benefits because they offer employers the opportunity to promote health and wellness among key employees. They can help identify and address potential health risks before they become serious, reducing medical costs and absenteeism over time.
“We are excited to partner with Dr. Burzynski and Houston Concierge Medicine,” said Dr. Customs. “We have seen many innovative and resourceful providers in the concierge medicine space lead the adoption curve regarding Epi+Gen CHD. Using epigenomics to drive accurate and personalized health decisions for their busy patients is being pushed forward by organizations like Houston Concierge Medicine.
“At Houston Concierge Medicine, we are committed to providing our patients with best-in-class diagnostic solutions. And since heart disease is top of mind for so many of our clients who work in fast-paced, stressful environments , the addition of Epi+Gen CHD will enable our practice to offer patients objective, non-invasive tests to determine their risk for heart disease. We are proud to partner with Cardio Diagnostics,” said Dr .Greg Burzynski.
About Houston Concierge Medicine
Houston Concierge Medicine & Wellness Center is a leading Houston medical practice serving wellness executives and consumers with best-in-class diagnostic and treatment solutions to promote and maintain health. For more information, please visit www.houstonconciergemedicine.com
About Cardio Diagnostics
Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized and accurate. The company was formed to further develop and commercialize an integrated genetic-epigenetic engine driven by Artificial Intelligence (AI).TM (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies to enable improved prevention, early detection and assistance in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project “, “budget”, “forecast”, “anticipate”, “intend”, “plan”, “may”, “will”, “should”, “believe” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations regarding future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals and the potential size and growth of or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause actual results to differ materially from expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and should not be relied upon by, an investor as a guarantee, assurance, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from the assumptions. Factors that could cause such changes include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the extent to which Epi+Gen CHD™, Cardio’s initial test, is accepted and approved by patients, healthcare professionals and other key channel participants; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s common stock on Nasdaq; changes in applicable laws or regulations; the Company’s inability to raise financing in the future; the Company’s inability to obtain and maintain clearance or regulatory approval for its tests, and any restrictions and limitations associated with any cleared or approved product; the Company’s inability to identify, license or acquire additional technology; the Company’s inability to maintain existing or future license, manufacturing, supply and distribution agreements; the Company’s inability to compete with other companies currently marketing or engaged in the development of products and services that may perform the same or similar functions as the Company’s products and services; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; pricing of the Company’s products and services and reimbursement for medical tests performed using the Company’s products and services; the Company’s estimates of expenses, future revenues, capital requirements and additional financing needs; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The Company cautions readers that the above list of factors is not exclusive and cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. The Company undertakes or disclaims any obligation or undertaking to publicly issue any update or revision of any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which such statement is based.